C.R. Bard (NYSE: BCR)‘s stock had its “market perform” rating reiterated by investment analysts at Northland Securities in a note issued to investors on Friday. They currently have a $111.00 target price on the stock.
C.R. Bard traded up 1.41% on Friday, hitting $100.968. C.R. Bard has a 1-year low of $93.69 and a 1-year high of $108.31. The stock’s 50-day moving average is currently $100.. The company has a market cap of $8.259 billion and a price-to-earnings ratio of 16.16.
C.R. Bard last announced its earnings results on Thursday, January 31st. The company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.03. The company had revenue of $762.60 million for the quarter, compared to the consensus estimate of $757.49 million. During the same quarter in the previous year, the company posted $1.70 earnings per share. The company’s revenue for the quarter was up 1.4% on a year-over-year basis. On average, analysts predict that C.R. Bard will post $6.28 earnings per share for the current fiscal year.
A number of other firms have also recently commented on BCR. Analysts at Northland Capital raised their price target on shares of C.R. Bard from $105.00 to $111.00 in a research note to investors on Friday. They now have a “market perform” rating on the stock. Separately, analysts at Barclays Capital reiterated an “overweight” rating on shares of C.R. Bard in a research note to investors on Friday, February 22nd. They now have a $112.00 price target on the stock. Finally, analysts at Goldman Sachs downgraded shares of C.R. Bard from a “neutral” rating to a “sell” rating in a research note to investors on Friday, February 22nd. They now have a $95.00 price target on the stock, up previously from $4.00.
Four equities research analysts have rated the stock with a buy rating, two have issued an overweight rating, fourteen have given a hold rating, and three have given a sell rating to the company. The company has a consensus rating of “hold” and a consensus target price of $104.06.
C. R. Bard, Inc. (Bard) is engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
